Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.
Testing for competitive inhibition of sparteine oxidation in the 9000 x g supernatant fraction from human liver provides an in vitro means to identify drugs which can bind to the same form of cytochrome P450 which oxidizes sparteine. There has so far been only two outcomes of this test: either the drug examined competed with sparteine for a common binding site, or it did not inhibit the reaction. The results of such in vitro testing implicated the involvement of guanoxan, nortriptyline, desipramine, imipramine, amitriptyline and chlorpromazine with this enzyme. Amobarbital, tolbutamide and guanethidine in therapeutic concentrations did not interfere with sparteine oxidation by this preparation.
D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D010084:Oxidation-Reduction; D013034:Sparteine / Q000378:metabolism*; D013237:Stereoisomerism; D013347:Subcellular Fractions
D000929:Antidepressive Agents, Tricyclic; D013034:Sparteine